Paq Therapeutics, Inc.
Clinical trials sponsored by Paq Therapeutics, Inc., explained in plain language.
-
New drug PT0511 targets tough KRAS cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called PT0511 in about 195 adults with advanced solid tumors that have a KRAS mutation or amplification, including colorectal, pancreatic, and lung cancers. The main goals are to check safety, find the best dose, and see how the drug works …
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 02:44 UTC
-
New hope for Hard-to-Treat cancers: experimental drug targets KRAS G12D mutation
Disease control Recruiting nowThis early-stage study tests a new drug called PT0253 in about 115 adults whose advanced solid tumors have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the best dose, and see how the body processes it. Participants must have meas…
Phase: PHASE1 • Sponsor: PAQ Therapeutics, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC